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HemagglutinationHemagglutination is an establishedmethod but has not been used previously to determine the efﬁcacy of virus
binding to a speciﬁc cellular receptor. Here we have utilized CD46-expressing erythrocytes from a transgenic
mouse to establish whether and to what extent the species B adenoviruses (Ads) as well as Ad37 and Ad49 of
species D can interact with CD46. A number of different agglutination patterns, and hence CD46 interactions,
could be observed for the different adenovirus types. In this systemAd7p, Ad11a, and Ad14 did not agglutinate
mouse erythrocytes at all. Hemagglutination of CD46 expressing erythrocytes with high efﬁciency was
observed for the previously established CD46 users Ad11p and Ad35 as well as for the less investigated Ad34.
Ad50 agglutinated with moderate efﬁciency. Ad16, Ad21 and Ad49 gave incomplete agglutination. Ad16 was
the only adenovirus that could be eluted. No speciﬁc CD46 interaction could be observed for Ad3p or for Ad37.å University, SE-901 85 Umeå,
.K. Andersson),
imi.umu.se (G. Wadell).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The currently classiﬁed 52 types of human adenoviruses have been
divided into seven species (A–G) (Jones et al., 2007). The species B
adenoviruses belong to two subgroups, B1 (Ad3, Ad7, Ad16, Ad21, and
Ad50) and B2 (Ad11, Ad14, Ad34, and Ad35) based on RFLP
differences indicated as substantial genome differences that provides
the rationale for classiﬁcation into B1 and B2 (Wadell et al., 1980a).
The majority of species B adenoviruses (Ads) have been reported to
use CD46 as a cellular receptor in a number of studies (Gaggar et al.,
2003; Segerman et al., 2003b; Sirena et al., 2004). There has also been
controversy concerning CD46 usage by Ad3, Ad7, and Ad14 (Fleischli
et al., 2007; Marttila et al., 2005; Sirena et al., 2004; Tuve et al., 2006).
Apparently at least Ad3 and Ad7 use another or an additional receptor,
sBAR (Segerman et al., 2003a). This is presumably identical to the
receptor designated X by Tuve et al. (2006), who also suggested a new
grouping of the species B adenoviruses based on their receptor usage.
Group I members (Ad16, -21, -35, -50) almost exclusively use CD46 as
a cellular receptor while group II members (Ad3, -7, -14) do not use
CD46 but another unknown receptor, and the solemember of group III
(Ad11p) uses both CD46 and another receptor (Tuve et al., 2006). The
species D types Ad37 and Ad49 have also been suggested to use CD46
as a cellular receptor. However, sialic acid is another receptor used by
Ad37 (Arnberg et al., 2000; Lemckert et al., 2006; Wu et al., 2004).
CD46, also known as membrane co-factor protein (MCP), is a
transmembrane glycoprotein expressed on all human nucleated cells,
but the extent of expression may vary between different cells (Riley-Vargas et al., 2004). CD46 is a regulatory protein in the complement
pathway, exerting its function by binding to C3b and C4b and
mediating their breakdown as a co-factor for complement factor I,
thereby preventing homologous complement attack of the host cell
(Liszewski et al., 1991; Oglesby et al., 1992; Riley-Vargas et al., 2004).
In order to ascertain the extent to which human Ads can interact
with human CD46 receptor molecules, we used transgenic mice
expressing human CD46 on the erythrocyte surface (Kemper et al.,
2001; Mrkic et al., 1998). Human erythrocytes do not express CD46
(Jonstone et al., 1993). Studies of virus receptor interactions on
established cell lines are complicated by the presence of additional
receptor molecules on the cell surface, i.e. sBAR for some species B Ads
is present on hematopoietic and epithelial cells (Segerman et al.,
2003a). The bioassay described here has not been exploited
previously; it was developed in order to assess the interaction
between Ads and CD46 speciﬁcally. As erythrocytes from syngeneic
non-transgenic C57BL/6 mice can be used as a control for interactions
with carbohydrates or other proteins, Ads that are agglutination
positive on CD46-erythrocytes but negative on control erythrocytes
must indeed be interacting with CD46. In view of the discrepant
reports on the extent of CD46 usage by different adenoviruses, we
have used this bioassay with a new methodological approach to
obtain more conclusive results (Fleischli et al., 2007; Marttila et al.,
2005; Sirena et al., 2004; Tuve et al., 2006).
Results
CD46-dependent hemagglutination
Complete agglutination of CD46 erythrocytes but not of control
erythrocytes was observed for Ad11p, Ad34, Ad35, and Ad50 (Figs. 1a,
2a, b and c). A summary of the agglutination properties of the Ads is
Fig. 1. a. Agglutination of CD46-RBCs by Ad11p and Ad16 after 1 h incubation at 37 °C. Serial two-fold dilution of virus from top to bottom well. Virus concentration in top well:
Ad11p, 4170 vp/cell; Ad16, 4790 vp/cell. Equal amount of RBC was added to each well. Virus particles per agglutinating unit: Ad11p, 16 vp/cell; Ad16, 37 vp/cell. b. Agglutination of
CD46-RBCs byAd11p and Ad16 after 1 h incubation at 37 °C followed by 1 h at 4 °C. c. Agglutination of control RBCs by Ad11p and Ad16. d. Left panel: agglutination of CD46-RBCs by
Ad37. Virus concentration in top well: 3100 vp/cell. Virus particles per agglutinating unit: 24 vp/cell. Right panel: agglutination of control RBCs by Ad37. Virus concentration in top
well: 3400 vp/cell. Virus particles per agglutinating unit: 53 vp/cell. All ﬁgures show results representative for at least two independent experiments.
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strength of the interaction between CD46-positive erythrocytes and
adenovirus particles, the number of physical virus particles per
erythrocyte constituting one hemagglutinating unit (HAU) was deter-
mined (vp/HAU). Even though a stronger interaction does not translate
directly into more efﬁcient transduction of target cells (Wang et al.,
2008), the exceptionally strong CD46 interaction for Ad11p, Ad34, and
Ad35 (vp/HAU 16, 30, and 15 vp/cell, respectively (Table 2)) is
compatible with the notion that CD46 can serve as a functional receptor.
This conclusion is supported by earlier studies of these types, which
demonstrate that all species B adenoviruses except Ad3 and Ad7 use
CD46 (Marttila et al., 2005; Sakurai et al., 2006; Segerman et al., 2003b).
Ad16 and Ad21 agglutinated CD46 erythrocytes incompletely
(Figs. 1a and 2d). Buttons of CD46 erythrocytes were formed but,
unlike the situation in agglutination-negative wells, these buttons did
not run. This incomplete agglutination was different from the partial
agglutination described by Rosen (Rosen, 1960), where the erythro-
cytes did not form a button but a partial lattice. Ad16 differed from the
other incompletely agglutinating types in that it could be eluted from
the erythrocytes by lowering the temperature (Fig. 1b). Addition of
salt (NaCl) did not change the agglutination pattern of Ad16p (data
not shown). The low vp/HAU for Ad16 indicates a strong interaction,
even though only incomplete agglutination could be observed. Ad21
agglutination also had this feature. The agglutinating capacities of the
adenovirus types investigated spanned a wide range. Ad11p was
equally efﬁcient as Ad35, 170 timesmore efﬁcient than Ad50, the least
efﬁcient completely agglutinating type, and 900 times more efﬁcientthan Ad49, which only achieved very incomplete agglutination at high
virus concentrations (Fig. 2e).
Ad3p and Ad37 agglutinated both CD46-RBCs and control RBCs
with similar efﬁciency, and this cannot be considered to be CD46-
speciﬁc attachment (Figs. 1d and 2f). Ad7p, Ad11a, and Ad14 did not
agglutinate CD46-RBCs or control RBCs and did not appear to interact
with CD46 in this hemagglutination assay (Figs. 2g, h and i).
Discussion
Hemagglutination is a well-established but currently seldom
employed method for assessment of ligand–receptor interactions.
We decided to use hemagglutination since it is a fast, clear-cut, and
biological method to determine how efﬁciently virions of each
adenovirus type reported to use CD46 as a receptor can bind to
CD46 expressed on the surface of transgenic mouse erythrocytes.
Hemagglutination can occur in different patterns. Complete
agglutination is deﬁned as all erythrocytes in the well being bound
to virus and being involved in the resulting lattice. When partial
agglutination occurs, a certain proportion of the erythrocytes become
bound and they form a lattice whereas the remaining erythrocytes are
unbound and form a button.
In a titration, a series of patterns can be observed until the endpoint
is reached. In incomplete agglutination the erythrocytes are bound but
not with enough strength to create a lattice. Incomplete agglutination is
apparent from buttons that do not run when the plate is tilted, and on
titration the pattern does not change until the endpoint has been
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and erythrocytes occurs and running buttons of unbound erythrocytes
are formed (see supplementary ﬁgure 1 for illustration of buttons of
negative and incomplete agglutination).Fig. 2. a. Left panel: agglutination of CD46-RBCs by Ad34. Virus concentration in top well: 120
panel: agglutination of CD46-RBCs by Ad35. Virus concentration in top well: 120 vp/cell. Vi
agglutination of CD46-RBCs byAd50. Tilted plate. Virus concentration in topwell: 7000 vp/cell.
agglutination of CD46-RBCs by Ad21. Tilted plate. Virus concentration in topwell: 1800 vp/cell
agglutination of CD46-RBCs by Ad49. Tilted plate. Virus concentration in top well: 17,500 vp/c
panel: agglutination of CD46-RBCs by Ad3p. Virus concentration in top well: 35,400 vp/cell
concentration in top well: 28,100 vp/cell. Virus particles per agglutinating unit: 14,100 vp
Agglutination of CD46-RBCs by Ad11a. i. Agglutination of CD46-RBCs by Ad14. All ﬁgures showIn this assay, we found that Ad11p, Ad34, Ad35, and Ad50 clearly
agglutinated CD46-expressing erythrocytes but not control erythro-
cytes with no CD46. Interestingly, Ad34 and Ad35 agglutinated
CD46-RBCs with the same efﬁciency as Ad11p (Table 2). These typesvp/cell. Virus particles per agglutinating unit: 30 vp/cell. Right panel: control RBCs. b. Left
rus particles per agglutinating unit: 15 vp/cell. Right panel: control RBCs. c. Left panel:
Virus particles per agglutinating unit: 1750 vp/cell. Right panel: control RBCs. d. Left panel:
. Virus particles per agglutinating unit: 450 vp/cell. Right panel: control RBCs. e. Left panel:
ell. Virus particles per agglutinating unit: 17,500 vp/cell. Right panel: control RBCs. f. Left
. Virus particles per agglutinating unit: 17,700 vp/cell. Right panel: control RBCs. Virus
/cell. g. Left panel: agglutination of CD46-RBCs by Ad7p. Right panel: control RBCs. h.
results representative for at least two independent experiments.
Table 1
Hemagglutination properties of Ad types that have been reported to bind to CD46.
Adenovirus type HA CD46tg-RBC HA control-RBC Elution at 4 °C
Ad3p + + −
Ad7p − − N.T.
Ad11p + − −
Ad11a − N.T. N.T.
Ad14 − N.T. N.T.
Ad16 ± − ±
Ad21 ± − −
Ad34 + − −
Ad35 + − −
Ad37 + + −
Ad49 ± − −
Ad50 + − −
Hemagglutination positive: + ; hemagglutination negative, running buttons: − ;
incomplete hemagglutination, buttons not running: ± ; not tested: N.T.
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use CD46 exclusively while Ad11p uses CD46 and an additional
unknown cellular receptor on hematopoietic and epithelial cells
(Segerman et al., 2003a; Tuve et al., 2006).
Comparing the ﬁber knobs of Ad11p to those of Ad34 and Ad35,
the amino acid identity is only around 50%. Ad34 and Ad35 have
serines in the key position 279 where Ad11p has arginine (Gustafsson
et al., 2006 ). This suggests that additional conformational features
contribute to an efﬁcient interaction between CD46 and the
adenovirus ﬁber knob.
The residues 279 and 280, critical for Ad11p CD46 interaction, are
conserved between Ad11p and Ad16 (Pache et al., 2008). However,
Ad16 has two additional residues in the FG loop and a deletion of two
residues in the IJ loop as compared to Ad11p (Pache et al., 2008).
Pache et al. suggested that these differences, in particular the steric
hindrance conferred by the longer FG loop, cause the afﬁnity between
the Ad16 ﬁber knob and CD46 to be about 70-fold lower than that
between the Ad11p ﬁber knob and CD46. Our ﬁnding that Ad16 can be
eluted from CD46-RBCs by lowering the temperature is consistent
with this. Ad16 apparently binds to CD46 and is able to agglutinate
CD46-RBCs incompletely, but the low afﬁnity between the ﬁber knob
and the receptor allows it to dissociate when the temperature is
lower. The interaction cannot be interrupted by introducing salt, as
can be done for the Ad37 sialic acid interaction (Arnberg et al., 2002),
and is apparently not charge-dependent (data not shown).
The insertion in the DG loop of Ad16 is also found in Ad3p. In
addition, the latter has a lysine at position 279. This might result in a
weaker interaction between the ﬁber knob and CD46.
There is some debate concerning the extent to which Ad3p and
Ad7p use CD46 as a receptor. Sirena et al. claimed that Ad3p uses
CD46 (Sirena et al., 2004), and so do Fleischli et al. (Fleischli et al.,Table 2
Physical virus particles constituting one hemagglutinating unit (HAU) for different
adenovirus types.
Ad type CD46tg-RBC (vp/cell) Control-RBC (vp/cell)
Ad3p 17,700 14,100
Ad11p 16 –
Ad16 37 (incomplete) –
Ad21 450 (incomplete) –
Ad34 30 –
Ad35 15 –
Ad37 24 53
Ad49 17,500 (incomplete) –
Ad50 1750 –
Values are means of at least two independent experiments.2007), who also presented evidence for CD46 usage by Ad7p. Marttila
et al. (Marttila et al., 2005) argued that all species B types except Ad3p
and Ad7p use CD46 and this conclusion is supported by the work of
Tuve et al. (Tuve et al., 2006). In our assay Ad3p appeared to bind
CD46-RBCs in the same manner as it bound to control RBCs, and it
would thus not be considered to speciﬁcally use CD46 on the
erythrocytes. In the study by Gaggar et al. (Gaggar et al., 2003), it
was concluded that Ad3 did not use CD46 as a high-afﬁnity
attachment receptor. This is in agreement with our results; we
found no signs of an Ad3p–CD46 interaction, although low-afﬁnity
binding could not be excluded entirely. Ad7p, on the other hand, did
not agglutinate either CD46-RBCs or control RBCs, supporting the
conclusion of Marttila et al. (Marttila et al., 2005), that Ad7p does not
use CD46.
The adenovirus types that do not bind CD46 – Ad7p, Ad11a, and
Ad14 – have all been associated with outbreaks of respiratory disease
(Chmielewicz et al., 2005; Metzgar et al., 2007; Wadell et al., 1980b;
Zhu et al., 2009). The authors of two studies that involved Ad14 have
suggested that it binds CD46 (Gaggar et al., 2003; Marttila et al.,
2005), while one study has shown that it does not (Tuve et al., 2006).
In a recent study, Persson et al. compared the interactions of CD46
with the ﬁber knobs of the three very similar types Ad11p, Ad7p, and
Ad14, and found that Ad11p binds to CD46 with much higher afﬁnity
(Persson et al., 2009). Ad7p, Ad11a, and Ad14 all have glutamine at
position 279, and even though this does not result in major
conformational changes it contributes to the reduced afﬁnity of
these types for CD46 (Mei and Wadell, 1993; Persson et al., 2009). In
our assay, Ad7p, Ad11a, and Ad14 were not able to bind to CD46 on
erythrocytes with high enough afﬁnity to establish agglutination,
while Ad11p agglutinated them with very high efﬁciency. Differences
in agglutination patterns between Ad11p and Ad11a have been
described previously; Ad11p but not Ad11a agglutinates erythrocytes
of rhesus and vervet monkeys (Mei and Wadell, 1993). This is
interesting, considering the high sequence identity in the ﬁber knobs
of these two types (Mei and Wadell, 1993). The same phenomenon
has however been observed for measles virus where the CD46-
binding Edmonston strain agglutinates rhesus erythrocytes whereas
the clinical isolates that use SLAM (CD150) do not agglutinate (Dorig
et al., 1993).
In 2006, Lemckert and co-workers (Lemckert et al., 2006) reported
that Ad49 of species D can also use CD46 but since then, no further
evidence to support this has appeared. Another species D type, Ad37,
has also been suggested to use CD46 but sialic acid is better known as
a receptor for this virus (Arnberg et al., 2000; Cashman et al., 2004;
Wu et al., 2004).
We have tested the interaction between these adenovirus types
and CD46 on the surface of erythrocytes expressing human CD46 in
the hemagglutination assay.
Ad37 was found to agglutinate CD46-RBCs and control RBCs with
the same efﬁciency, which indicates that agglutination is independent
of CD46 expression and most likely due to the presence of sialic acid
on the surface of both types of erythrocytes. This does not, however,
rule out the possibility that Ad37 might still be able to bind to CD46.
Ad49 agglutinated CD46 erythrocytes to some extent at high
concentrations of virus. There is apparently a weak interaction
between Ad49 and CD46.
We have described a robust and versatile assay for determination of
the interactions between Ads and CD46. Using this system,we conclude
that Ad11p, Ad34, and Ad35 were outstanding at binding CD46. Ad21
and Ad50 were intermediate, and Ad49 was a very weak binder.
Noteworthy is that a recent study on Ad21 interaction with CD46 by
surface plasmon resonance reaches similar conclusions on the relative
afﬁnity of theCD46 interactionswithAd11p, Ad35 andAd21ﬁber knobs
(Cupelli et al., 2010). Ad16p had unique features, as it allowed
incomplete agglutination of CD46-RBCs down to a few vp/HAU and
this agglutination became weaker at reduced temperature. None of the
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adenovirus types that in the literature have given discrepant results, i.e.
Ad3p, Ad7p, and Ad14, did not appear to bind to CD46 in this assay.Materials and methods
Viruses
The adenoviruses used in this study were Ad3p (p = prototype,
strain GB), Ad7p (strain Gomen), Ad11p (strain Slobitsky), Ad11a
(BC34) (Li et al., 1991), Ad14p (strain DeWit), Ad16p (strain CH79),
Ad21 (strain 1645), Ad34 (strain Compton), Ad35 (strain Holden),
Ad37p (strain 1477), Ad49 (strain T87-677) (Schnurr and Dondero,
1993), and Ad50 (strain Wan). The viruses were all propagated in
A549 cells and puriﬁed on a discontinuous CsCl gradient as described
previously (Mei et al., 1998). The virus band was collected and den-
sity was measured using a refractometer. Virions were desalted on a
NAP-10 column (GE Healthcare, Buckinghamshire, UK) and eluted
with 1.5 ml 10 mM PBS. Virion concentration was determined by
spectrophotometry; 1 OD unit (OD260 – OD330) corresponds to 280 µg
virions or 1012 virus particlesml−1 (Mei et al., 1998). The identity of the
adenovirus types was conﬁrmed by DNA restriction analysis (Adrian
et al., 1986).Hemagglutination
The CD46-transgenic mice on a B6C3F1 background were kindly
provided by Dr Roberto Cattaneo via Dr Ann-Beth Jonsson,
Karolinska Institutet, Stockholm. C57BL/6 mice were kindly provid-
ed by Dr Helena Edlund, Umeå University. The animals were bred at
the animal facility and all procedures were performed according to
institutional guidelines. Mouse blood was collected in Alsever's
solution and centrifuged at 1500 rpm for 5 min at RT. The
erythrocytes were washed twice in PBS. They were diluted to a 1%
suspension in PBS (v/v). They were also counted in a Bürker
chamber. Fifty microliters of PBS was added to the wells of a 96-
well microtiter v-plate (Sarstedt, Newton, NC). Virions were then
added in a range of 5×1010 to 1.7×1011 followed by serial 2-fold
dilutions. Thereafter, 50 µl of the 1% erythrocyte suspension was
added to each well and the plate was incubated at 37 °C for 1 h, in
some cases followed by incubation at 4 °C for 1 h. For the NaCl
experiment, 40 µl NaCl solutionswere added to thewells followed by
addition of 8 HA units Ad16p virion. The ﬁnal concentrations of NaCl
ranged from 0.15 M to 0.9 M. Thereafter, 50 µl of the 1% erythrocyte
suspension was added to each well and the plate was incubated at
37 °C for 1 h followed by incubation at 4 °C for 1 h. The result was
visually interpreted as being agglutination positive in wells in which
a lattice had formed and agglutination negative in wells where a
button had formed in the bottom. Final determination of hemagglu-
tination was done by tilting the plate and observing whether or not
the buttons ran. Running buttons were scored as deﬁnitely
hemagglutination negative, whereas buttons that did not run were
considered to be incomplete agglutination. In order to obtain a
quantitative estimate of the strength of the interaction between
CD46-positive erythrocytes and adenovirus particles, the number of
physical virus particles needed per cell to establish agglutinationwas
determined (Table 2).CD46 expression on erythrocytes
To ascertain that CD46 was actually expressed on the erythrocytes
from the CD46-transgenic mice; all mice were analyzed for the
presence of the CD46 gene and FACS scan was used to detect CD46
expression on the erythrocyte surface (data not shown).Genotype analysis
Every CD46 transgenic mouse was analyzed for the presence of the
CD46 gene. Tails from mice were cut (0.3–0.5 cm in length) and DNA
was prepared using the QIAamp DNA Blood Mini kit (QIAGEN, Solna,
Sweden) according to the manufacturer's instructions. CD46-speciﬁc
PCR was carried out based on two primer pairs: 5′-AAAGGGCAAAT-
TACCTTAAGGGGTG and 5′-AGCACTTCGACCTAAAAATAGAGAT, ampli-
fying 263 bp of the CD46 promoter region; and 5′-GCCAGTTCATCTTTT-
GACTCTATTAA and 5′-CAGCATATCCCTGCTTTAATACAAC, amplifying
249 bp of exon 14 (DNA Technology A/S, Aarhus, Denmark) (Mrkic
et al., 1998).
FACScan ﬂow cytometry
Approximately 5×105 washed erythrocytes in PBS were pelleted
by centrifugation at 1500 rpm for 5 min and resuspended in anti-
CD46 antibody (H294 rabbit polyclonal IgG; Santa Cruz Biotechnology
Inc., Santa Cruz, CA) diluted 1:200 in PBS containing 2% FBS. The cells
were incubated for 1 h on ice at 4 °C. The cells were then washed
twice in PBS containing 2% FBS and incubated with an FITC-
conjugated secondary antibody (Swine anti-rabbit IgG; Dako,
Glostrup, Denmark) for 1 h on ice at 4 °C. After washing as described
above, the cells were resuspended in PBS and analyzed in a FACScan
ﬂow cytometer (Becton Dickinson) using CELLQUEST software.
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